Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study
Background Obesity is associated with an increased risk of developing clear cell renal cell
carcinoma (RCC) but, paradoxically, obesity is also associated with improved oncological …
carcinoma (RCC) but, paradoxically, obesity is also associated with improved oncological …
Novel emerging biomarkers to immunotherapy in kidney cancer
Y Ged, MH Voss - Therapeutic Advances in Medical …, 2021 - journals.sagepub.com
The treatment of metastatic renal cell carcinoma has significantly evolved in recent years,
particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking …
particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking …
Metastatic chromophobe renal cell carcinoma: Presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes
Y Ged, YB Chen, A Knezevic, J Casuscelli… - Clinical genitourinary …, 2019 - Elsevier
Background Sarcomatoid features (SF) in renal cell carcinoma (RCC) denote poor
prognosis. Data for metastatic chromophobe RCC (ChRCC) with SF are limited. We studied …
prognosis. Data for metastatic chromophobe RCC (ChRCC) with SF are limited. We studied …
Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
Y Ged, CH Lee - Expert Review of Anticancer Therapy, 2022 - Taylor & Francis
Introduction The treatment landscape of metastatic renal cell carcinoma (RCC) has
significantly evolved in recent years with the advent and approval of multiple combinations …
significantly evolved in recent years with the advent and approval of multiple combinations …
[HTML][HTML] DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy
Y Ged, JL Chaim, RG DiNatale, A Knezevic… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Loss-of-function alterations in DNA damage repair (DDR) genes are associated
with human tumorigenesis and may determine benefit from immune-oncology (I/O) agents …
with human tumorigenesis and may determine benefit from immune-oncology (I/O) agents …
Comprehensive molecular characterization and response to therapy in fumarate hydratase–deficient renal cell carcinoma
JP Gleeson, I Nikolovski, R Dinatale, M Zucker… - Clinical Cancer …, 2021 - AACR
Purpose: Fumarate hydratase–deficient renal cell carcinoma (FH-RCC) is a rare, aggressive
form of RCC associated with hereditary leiomyomatosis and RCC syndrome. Evidence for …
form of RCC associated with hereditary leiomyomatosis and RCC syndrome. Evidence for …
[HTML][HTML] A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response
There is conflicting data regarding the role of PBAF complex mutations and response to
immune checkpoint blockade (ICB) therapy in clear cell renal cell carcinoma (ccRCC) and …
immune checkpoint blockade (ICB) therapy in clear cell renal cell carcinoma (ccRCC) and …
Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with …
Purpose: High body mass index (BMI) may lead to improved immune-checkpoint blockade
(ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a …
(ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a …
The shifting treatment paradigm of metastatic renal cell carcinoma
The treatment landscape of renal cell carcinoma is rapidly evolving, especially with the
introduction and approval of immune checkpoint inhibitor combination therapies. Clinical …
introduction and approval of immune checkpoint inhibitor combination therapies. Clinical …